Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection
Chronic Hepatitis B
About this trial
This is an interventional treatment trial for Chronic Hepatitis B focused on measuring Hepatitis B Virus, Chronic Hepatitis B, HBV, Hepatitis
Eligibility Criteria
Inclusion Criteria:
- Male or female of ages 18 - 65
- Chronic HBV infection for >/= 6 months
Exclusion Criteria:
- Any clinically significant chronic or acute medical condition that makes the volunteer unsuitable for participation
- Significant fibrosis or cirrhosis
- History or evidence of drug or alcohol abuse
- History of intolerance to SC injection
- History of chronic liver disease from any cause other than chronic HBV infection
- History of hepatic decompensation
- Any prior receipt of an interferon product
Sites / Locations
- Investigative Site
- Investigative Site
- Investigative site
- Investigative Site
- Investigative Site
- Investigative Site
- Investigative Site
- Investigative Site
- Investigative Site
- Investigative Site
- Investigative Site
- Investigative Site
- Investigative Site
- Investigative Site
- Investigative Site
- Investigative Site
- Investigative Site
- Investigative Site
- Investigative Site
- Investigative Site
- Investigative Site
- Investigative Site
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm 7
Arm 8
Arm 9
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Cohort 1d
Cohort 2d
Cohort 3d
Cohort 1e
Cohort 2e
Cohort 3e
Cohort 1f
Cohort 2f
Cohort 3f
VIR-2218 given by subcutaneous injection
VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
VIR-2218 given by subcutaneous injection
VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection